Shares of Xeris Pharmaceuticals Inc (XERS) soared 5.33% in the pre-market session on Friday, following analysts raising their price targets on the stock.
Piper Sandler raised its price target on Xeris Biopharma to $4 from $3, while maintaining a Neutral rating. H.C. Wainwright also boosted its price target to $8 from $6.60 and reiterated a Buy rating on the shares.
The positive analyst actions reflect optimism around Xeris Pharmaceuticals' prospects, driving the stock's significant upward movement during this morning's trading session.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。